New combo therapy shows promise for myeloma patients with remaining disease

This study looked at 42 people with multiple myeloma that was still present after a stem cell transplant. It compared continuing lenalidomide alone versus adding two other drugs (ixazomib and dexamethasone) to try to eliminate the remaining cancer. The goal was to see which approach better cleared the disease, as measured by a sensitive test for minimal residual disease (MRD).